Most patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed with advanced disease and survive less than 12 months 1 . PDAC has been linked with obesity and glucose intolerance [2] [3] [4] , but whether changes in circulating metabolites are associated with early cancer progression is unknown. To better understand metabolic derangements associated with early disease, we profiled metabolites in prediagnostic plasma from individuals with pancreatic cancer (cases) and matched controls from four prospective cohort studies. We find that elevated plasma levels of branched-chain amino acids (BCAAs) are associated with a greater than twofold increased risk of future pancreatic cancer diagnosis. This elevated risk was independent of known predisposing factors, with the strongest association observed among subjects with samples collected 2 to 5 years before diagnosis, when occult disease is probably present. We show that plasma BCAAs are also elevated in mice with early-stage pancreatic cancers driven by mutant Kras expression but not in mice with Kras-driven tumors in other tissues, and that breakdown of tissue protein accounts for the increase in plasma BCAAs that accompanies early-stage disease. Together, these findings suggest that increased whole-body protein breakdown is an early event in development of PDAC.
Most patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed with advanced disease and survive less than 12 months 1 . PDAC has been linked with obesity and glucose intolerance [2] [3] [4] , but whether changes in circulating metabolites are associated with early cancer progression is unknown. To better understand metabolic derangements associated with early disease, we profiled metabolites in prediagnostic plasma from individuals with pancreatic cancer (cases) and matched controls from four prospective cohort studies. We find that elevated plasma levels of branched-chain amino acids (BCAAs) are associated with a greater than twofold increased risk of future pancreatic cancer diagnosis. This elevated risk was independent of known predisposing factors, with the strongest association observed among subjects with samples collected 2 to 5 years before diagnosis, when occult disease is probably present. We show that plasma BCAAs are also elevated in mice with early-stage pancreatic cancers driven by mutant Kras expression but not in mice with Kras-driven tumors in other tissues, and that breakdown of tissue protein accounts for the increase in plasma BCAAs that accompanies early-stage disease. Together, these findings suggest that increased whole-body protein breakdown is an early event in development of PDAC.
PDAC is a leading cause of cancer-related death worldwide, and most patients have incurable disease at diagnosis 1 . The best-characterized predisposing factors, current tobacco use and a first-degree relative with PDAC, both impart an approximate 1.8-fold increased risk for the disease 5, 6 . These risk factors, however, have thus far provided limited insight into the biology of early disease progression of sporadic tumors. Development and progression of PDAC is also associated with altered systemic metabolism including obesity 2 , glucose intolerance 3, 4 and cancer-induced cachexia 7 . Nevertheless, no systematic examination of circulating metabolites has been performed to determine whether altered metabolism may indicate subclinical pancreatic cancer or inform understanding of early disease progression when interventions might improve patient outcomes.
Prior efforts to identify changes in circulating metabolites related to cancer have employed a cross-sectional design, comparing cancerfree subjects to affected individuals with blood samples collected at diagnosis [8] [9] [10] . This approach is problematic for discovery of changes related to early cancer progression, as consequences of advanced disease are likely to have an impact on circulating metabolite profiles. This is particularly true for patients with pancreatic cancer, who commonly have significant anorexia, weight loss and pancreatic insufficiency at the time of diagnosis 1 . To investigate how altered metabolism might contribute to pancreatic malignancy, we profiled 1 1 9 4 VOLUME 20 | NUMBER 10 | OCTOBER 2014 nature medicine plasma metabolites in cases with PDAC and matched controls drawn from four prospective cohort studies with blood collected at least 2 years before cancer diagnosis (Supplementary Table 1 ). The median time between blood collection and PDAC diagnosis was 8.7 years.
In conditional logistic regression models, levels of 15 metabolites were associated with future diagnosis of PDAC to P < 0.05; three metabolites, the BCAAs isoleucine, leucine and valine were significant to P ≤ 0.0006, the predefined significance threshold after correction Table 2) .
To evaluate the magnitude of risk for PDAC diagnosis, we divided participants into quintiles of increasing BCAA levels. Compared to the bottom quintile, subjects in the top quintile had at least a two-fold increased risk of developing PDAC ( Table 1, Supplementary Table 3 and Supplementary Fig. 1 ). As noted previously 11 , circulating levels Figure 2 Plasma BCAA levels are elevated during subclinical disease. (a) Graph of odds ratio (error bars indicate 95% confidence interval (CI)) for future pancreatic cancer diagnosis among cohort cases and matched controls comparing highest versus lowest quintiles of circulating BCAA levels stratified by time from blood collection to the case's cancer diagnosis. Odds ratio was determined from conditional logistic regression models conditioned on matching factors and adjusted for age at blood draw (years, continuous), fasting time (<4 h, 4-8 h, 8-12 h, ≥12 h, missing) and race or ethnicity (white, black, other, missing). Red horizontal line marks an odds ratio of 1.0. The number of cases and controls in each time period and association results for the individual BCAAs are provided in Supplementary Table 6 . (b) Graph of mean (±s.e.m.) total plasma BCAA concentration in LSL-Kras G12D/+ ; LSL-Trp53 R172H/+ ; Pdx1-cre (KPC) mice over time and in littermate controls lacking either LSL-Kras G12D or Pdx1-cre or both. Each control data point is an average for one mouse over the course of the study ( Supplementary Fig. 4b) , and values for KPC mice living longer than 19 weeks are averaged for the >19-weeks time point. For weeks 15-17, n = 6 KPC and n = 9 control, Student's t-test, P = 0.001. For >19 weeks, n = 4; 11-13 weeks, n = 6; 7-9 weeks, n = 7; 3-5 weeks, n = 9. (c) H&E staining of pancreatic tissue obtained from KP −/− C mice and littermate controls at 3-4 weeks of age. Tissues are from a control mouse with histologically normal pancreas (left) a KP −/− C mouse with areas of PDAC adjacent to areas of normal pancreas (middle) and a KP −/− C mouse with areas of PDAC and pancreatic intraepithelial neoplasia (arrowheads; right). Scale bars, 50 µm. Table 4 ), reflecting their common pathways of metabolism 12 and leading to similar results for the sum total of BCAAs ( Table 1 and  Supplementary Table 3) . Circulating BCAAs are elevated in obese individuals and those with insulin resistance 13 . In study participants, plasma BCAA levels modestly correlated with markers of energy balance, obesity and glucose intolerance (Supplementary Table 4) . To evaluate the independent effect of BCAAs on PDAC risk, we assessed models that included these markers and found that the odds ratios for PDAC remained largely unchanged ( Table 1) . Elevated circulating levels of BCAAs are also associated with future risk of diabetes 11, 14 . As type 2 diabetes is a predisposing factor for PDAC 15 , we questioned whether the intermediate development of diabetes underlied the association of BCAAs with future PDAC diagnosis. Exclusion of subjects with diabetes at blood collection did not change our results ( Table 1 ), indicating that we had not identified a signature of prevalent diabetes associated with later PDAC diagnosis. To determine whether increased circulating BCAAs identify a population at risk for diabetes, who are then at elevated risk of PDAC, we excluded subjects who developed diabetes between the time of blood collection and cancer diagnosis and found the results unchanged ( Table 1 ). These data suggest that the association of circulating BCAAs with future PDAC diagnosis is not dependent on intermediate development of diabetes.
To examine the contribution of circulating BCAAs to risk stratification models for PDAC, we evaluated the area under the curve (AUC) of receiver-operating-characteristic (ROC) curves 16 and net reclassification improvement (NRI) 17 with low-risk and high-risk categories. Compared to the base model, including circulating BCAAs led to a significant increase in AUC (Supplementary Table 5a and Supplementary Fig. 2 ) and a net 8.2% of cases moving to the highrisk category with an NRI of 5% (Supplementary Table 5b) . Thus, in our population, inclusion of circulating BCAAs in risk stratification models improved the ability to identify future PDAC cases.
In stratified analyses, we noted no significant differences in the association of BCAAs with PDAC by cohort, sex, smoking status, body-mass index (BMI) or fasting status at blood collection ( Supplementary Fig. 3 , all interaction P ≥ 0.14). To examine when circulating BCAAs were most associated with PDAC, we stratified cases and matched controls by time interval between blood collection and PDAC diagnosis (<2 years, 2 to <5 years, 5 to <10 years and ≥10 years). These analyses demonstrated particularly strong associations between elevated BCAAs at 2-5 years before diagnosis and future PDAC diagnosis (Fig. 2a and Supplementary Table 6 ).
Experimental studies indicate years elapse between formation of the initial malignant clone and cancer diagnosis 18 , suggesting that occult PDAC might have been present at the time points showing the strongest associations with elevated BCAAs. We therefore hypothesized that elevated circulating BCAAs are a marker of early PDAC. To test this possibility, we conducted a prospective serial blood sampling study using lox-stop-lox (LSL)-Kras G12D/+ ; LSL-Trp53 R172H/+ ; Pdx1-cre (KPC) mice, which develop PDAC with variable latency 19 . KPC mice progress through all histological stages of disease, from normal pancreata to invasive adenocarcinoma, with a median survival of approximately 21 weeks 19 ( Supplementary Fig. 4a ). KPC mice initially displayed similar BCAA levels to littermate controls, but they developed significant elevations from 15-17 weeks before death ( Fig. 2b and Supplementary Fig. 4b ). These data suggest circulating BCAA elevations accompany early PDAC.
LSL-Kras G12D/+ ; Trp53 flox/flox ; Pdx1-cre (KP −/− C) mice develop PDAC with more consistent kinetics, displaying precursor lesions with limited invasive cancer by 3-4 weeks of age ( Fig. 2c) and a median lifespan of 10-12 weeks 20 . In mice at 3-4 weeks of age, we observed no difference in body weight or food consumption between KP −/− C mice and littermate controls lacking either Pdx1-Cre or LSL-Kras G12D or both, suggesting animals with early PDAC had not yet developed overt constitutional symptoms ( Fig. 2d and Supplementary Fig. 4c ). Consistent with findings in patients and KPC mice, circulating BCAA levels were higher in KP −/− C animals with subclinical PDAC when compared with those in littermate control mice (Fig. 2e) , a pattern not observed for most other amino acids ( Fig. 2f and Supplementary  Fig. 4d ,e) We observed no significant differences in fasting blood Figure 3 BCAA elevations are derived from a long-term pool of amino acids. (a) Plasma levels (mean ± s.e.m.) of 13 C-labeled leucine (M+6) and 13 C-labeled valine (M+5) normalized to food intake over time following a two-hour exposure to diets containing 13 C-labeled leucine and 13 C-labeled valine (n = 8 KP −/− C, n = 6 control). The time points correspond to the red arrowheads in the diagram. (b) Diagram of experiment using labeled diets to investigate contributions to plasma BCAA levels from longterm pools. Two cohorts of mice were used for these experiments, one killed in the fed state and a second killed in the fasted state at the time points indicated by the red arrowheads. We examined whether malignancies in other tissues induced by the same genetic lesions could cause elevated plasma BCAA levels. Cre recombinase introduction into lung or muscle of mice with the LSL-Kras G12D and Trp53 flox/flox alleles from the KP −/− C model leads to non-small-cell lung cancer and sarcoma, respectively [21] [22] [23] . Neither model displayed the BCAA alterations seen with early PDAC (Supplementary Fig. 5 ). Subcutaneous and orthotopic implantation of cancer cell lines derived from the KP −/− C model into immunocompetent syngenic hosts both also failed to cause elevated BCAA levels (Supplementary Fig. 6 ). These data argue that elevations in BCAAs are associated with early-stage autochthonous tumors arising in the pancreas and are not a general feature of Kras-driven cancer. They also suggest that implantation of cells from end-stage disease does not model the early disease state that results in BCAA elevations.
Chronic pancreatitis is a risk factor for human PDAC 24 , and pancreatic inflammation can promote PDAC development and progression in mice 25, 26 . Therefore, we examined whether BCAA elevations might be a cause or consequence of pancreatic inflammation in early disease in mice. Mild, chronic pancreatitis induced by caerulein in the absence of tumorigenesis failed to cause elevations in BCAAs ( Supplementary  Fig. 7a-h) , and prolonged increases in plasma BCAA levels caused by dietary interventions did not cause pancreatic inflammation or pancreatitis ( Supplementary Fig. 7i-o) . Nevertheless, further studies are needed to understand the relationship between BCAAs and more severe pancreatitis.
Unlike levels of other amino acids, plasma BCAA levels are not regulated by the liver 27, 28 ; instead, levels are determined by dietary uptake, tissue utilization and breakdown of muscle and other body protein stores 27, 29 . Therefore, plasma BCAAs may originate from short-term pools related to dietary uptake and disposal or longterm pools related to breakdown of tissue proteins. To determine the involvement of the short-term pool, we fed 4-week-old KP −/− C mice and littermate control mice lacking either Pdx1-Cre or LSL-Kras G12D or both a defined amino acid diet, in which 20% of leucine and valine were 13 C labeled. KP −/− C and control mice consumed similar amounts of food when exposed to labeled diet for 2 h (Supplementary Fig. 8a) , and we observed no difference in appearance and disappearance of plasma 13 C label ( Fig. 3a and Supplementary Fig. 8b ), arguing that gut uptake and peripheral disposal of BCAAs are similar in mice with or without PDAC.
To determine the contribution of long-term BCAA pools to plasma levels, we exposed mice to labeled diet during a period of rapid growth in early life and then switched them to unlabeled diet for 3 d to chase label from the short-term pool (Fig. 3b) . Despite similar peripheral tissue protein labeling ( Fig. 3c and Supplementary Fig. 8c) , the fraction of labeled BCAAs in plasma was elevated in 4-week-old KP −/− C mice relative to that in littermate controls (Fig. 3d) . Furthermore, by comparing the amount of label in plasma under fed conditions, encompassing both labeled long-term and unlabeled short-term pools, to that under fasted conditions, in which only labeled long-term pools contribute, we calculated that increased liberation of BCAAs from long-term body stores was solely responsible for the elevations in BCAAs in KP −/− C mice (Fig. 3d,e and Supplementary Fig. 8d ). These data suggest that an early consequence of PDAC is enhanced breakdown of tissue proteins leading to elevated plasma BCAA levels. Consistent with this hypothesis, KP −/− C mice with early PDAC had smaller fast-twitch muscles with no changes in slow-twitch and cardiac muscle weight (Fig. 3f and Supplementary Fig. 9 ). Notably, muscle atrophy associated with prolonged fasting and late-stage malignancy exhibits a similar pattern [30] [31] [32] .
Increased muscle catabolism represents one aspect of cancerassociated cachexia, a wasting syndrome frequently affecting patients with advanced PDAC and contributing to worse outcomes [33] [34] [35] [36] . Our findings, however, suggest that protein breakdown begins much earlier than previously appreciated and predates onset of clinical cachexia. Inflammatory cytokines produced by immune and/or tumor cells have been implicated in cachexia 31, 37 , and the low disease burden at the time of BCAA elevation suggests hormonal factors may be involved in early PDAC to cause these elevations as well. Liberation of tissue amino acids could support the elevated amino acid requirements of pancreatic cancer cells 38, 39 , with BCAAs and/or other amino acids derived from tissue breakdown contributing to disease progression. Because hepatic metabolism maintains relatively constant plasma levels of all amino acids except BCAAs 27, 29, 40 , increased liberation of tissue amino acids would be expected raise BCAA concentrations in blood. The association between elevated BCAA levels and other metabolic disease states 11, 13, 14, 41 suggests that high plasma BCAA concentrations could be a general marker of increased protein turnover, and elevated BCAA levels could contribute to the peridiagnostic hyperglycemia commonly found in patients with PDAC 42 .
In participants from four large prospective cohorts, circulating BCAAs were associated with future diagnosis of PDAC. We observed similar BCAA elevations in two mouse models of PDAC and demonstrated that these elevations result from breakdown of peripheral protein stores. These findings provide new insight into how early disease affects whole-body metabolism and suggest that muscle protein loss occurs much earlier in disease progression than previously appreciated.
METhODS
Methods and any associated references are available in the online version of the paper. We included incident pancreatic adenocarcinoma cases diagnosed after blood collection through 2010 with available plasma and no prior history of cancer. Cases were identified by self-report or follow-up of deaths. Deaths were ascertained from next-of-kin, postal service or National Death Index; this method captures >98% of deaths 43 . Medical records were reviewed by physicians blinded to exposure data to confirm pancreatic cancer diagnoses. Similar to prior studies in these cohorts 4, [44] [45] [46] and based on a predefined analysis plan, we included only cases diagnosed ≥2 years after blood collection, as the weight loss and insulin resistance that develop due to pancreatic cancer manifest in the 2 years before diagnosis 42, 47 . For each case, we randomly selected two controls, matching on cohort (also matches on sex), year of birth (±5 years), smoking status (never, past, current, missing), fasting status (<8 h, ≥8 h), and month/year of blood collection (±3 months in HPFS, ±3 months in NHS, ±6 months in PHS, and exact matching in WHI). Controls were alive without cancer at the case's diagnosis date and provided a blood sample. Covariate data were obtained from baseline questionnaires in PHS and WHI and questionnaires before blood collection in HPFS and NHS, as described previously 4, 45 . In HPFS, NHS, and PHS, cancer stage among cases was directly classified based on medical record review as local disease amenable to surgical resection, locally advanced disease that is unresectable but without distant metastases, or distant metastatic disease. In WHI, medical records were coded using Surveillance Epidemiology End Results summary staging, which classifies tumors as localized, regional, or distant. These stages were then classified in the same manner as in HPFS, NHS and PHS, as local, locally advanced, and metastatic disease, respectively.
The initial data set included 454 cases and 908 controls. Seven controls had insufficient plasma for metabolite profiling. One case and one control were excluded due to missing data for >10% of metabolites. Table S1 . Blood samples in HPFS and NHS were collected by participants, mailed overnight on cold packs, and then spun to collect and store plasma (delayed processing), whereas PHS and WHI participants' whole blood was separately immediately into plasma and stored. An overview of procedures for collection and storage of samples from each cohort is provided below and summarized in Supplementary Note, Table S2 .
Health Professionals Follow-up Study. Upon arrival at the blood lab, vials were centrifuged in order to separate the various component parts. Cryo storage tubes were labeled with the appropriate study member's ID number, and the separated blood components were pipetted into them. This process produced 5 tubes of plasma, 2 tubes of white blood cells, and 1 tube of red blood cells for each cohort member. The tubes were then stored in liquid nitrogen freezers. A bulk tank, holding up to 3,000 gallons of liquid nitrogen, automatically feeds each individual freezer whenever the freezer's sensors indicate that coolant is required.
Nurses' Health Study. Blood samples were separated into components (plasma, white blood cells and red blood cells) and pipetted into 8 cryotubes with 5 tubes of plasma, 2 tubes of white blood cells and 1 tube of red blood cells. Samples were immediately frozen in vapor-phase liquid nitrogen freezers. The NHS Blood Lab stores all biologic samples associated with the Blood Study in-house in a large liquid nitrogen freezer farm. The cryotubes are stored in the vapor phase of liquid-nitrogen freezers; the highest freezer temperature is −130 °C near the top of the freezer, and the lowest temperature is −196 °C at the bottom near the liquid nitrogen. All freezers are alarmed and monitored continuously either by NHS laboratory staff or a central security desk (nights and weekends).
Physicians' Health Study. Blood collection kits were sent to all participants with instructions to have blood drawn into the EDTA tubes that were provided. Two tubes were centrifuged for plasma, and a third tube was for whole blood. The specimens were received in the laboratory on chill packs within 24 h of being drawn. Upon receipt, the samples were refrigerated and re-aliquotted into nine 1.2-mL tubes (three whole blood and six plasma), all frozen at −82 °C.
Women's Health Initiative: Blood samples were collected on all WHI-OS participants at a baseline clinic visit in the fasting state. Blood samples were maintained at 4 °C for up to one hour until plasma or serum was separated from cells. Centrifuged aliquots were put into −70 °C freezers within two hours of collection. Samples were shipped frozen by overnight delivery to a central facility and kept within −70 °C freezers.
Plasma samples were grouped based on cohort, so that all cases and controls from a single cohort study underwent metabolite profiling as a batch. Sample triplets (pancreatic cancer case, matched control #1, and matched control #2) were distributed randomly within the batch, and the order of the case and two matched controls within each triplet was also randomly designated. Therefore, the case and its two controls were always run in the same batch and were always directly adjacent to each other in the analytic run, thereby limiting variability in platform performance across matched case-control triplets.
For participants from all four cohorts, plasma samples were thawed once to aliquot them from large-volume vials into the smaller volumes needed for shipment to the Broad Institute of the Massachusetts Institute of Technology and Harvard University (Cambridge, MA). The samples were refrozen at the Broad Institute and then thawed a second time to perform metabolite profiling. Therefore, for all cases and controls, plasma samples had been thawed twice at the time of metabolite profiling.
We previously measured hemoglobin A1c (HbA1c) in 389 cases and 757 controls in the laboratory of N. Rifai (Children's Hospital, Boston, MA) using reagents from Roche Diagnostics (Indianapolis, IN). We measured plasma insulin in 386 cases and 743 controls, plasma proinsulin in 388 cases and 746 controls, and plasma C-peptide in 408 cases and 785 controls using reagents from Diagnostic Systems Laboratory (Webster, TX) and Millipore Corporation (Billerica, MA). Randomly inserted samples from quality control (QC) plasma pools had mean intra-assay coefficients of variance (CVs) of 2.0% for HbA1c, 5.4% for insulin, 3.1% for proinsulin, and 4.9% for C-peptide 4 .
Metabolite profiling. Profiles of endogenous polar metabolites were obtained using liquid chromatography-tandem mass spectrometry (LC-MS) at the Broad Institute of the Massachusetts Institute of Technology and Harvard University (Cambridge, MA). The LC-MS methods were designed to enable broad measurement of metabolic markers and intermediates, including metabolites from central metabolism and amino acid metabolism, using low plasma sample volumes 48 . LC-MS parameters for targeted analyses, including chromatographic retention times and mass spectrometry multiple reaction monitoring settings (declustering potentials, collision energies, and lens voltages), were determined using over 300 commercially available reference compounds. A subset of 133 polar metabolites were measurable in plasma using a combination of two distinct hydrophilic interaction liquid chromatography (HILIC) methods, one operated under acid mobile phase conditions with positive-ion-mode MS detection and the other under basic elution conditions with negative-ion-mode MS detection.
The acidic HILIC method using positive-ionization-mode MS analyses was similar to the method described by Wang et al. 11 . Briefly, the LC-MS system consisted of a 4000 QTRAP triple quadrupole mass spectrometer (AB SCIEX) coupled to an 1100 Series pump (Agilent) and an HTS PAL autosampler (Leap Technologies). Plasma samples (10 µL) were extracted using nine volumes of 74.9:24.9:0.2 (v/v/v) acetonitrile/methanol/formic acid containing stable npg isotope-labeled internal standards (valine-d8, Isotec; and phenylalanine-d8, Cambridge Isotope Laboratories). The samples were centrifuged (10 min, 9,000g, 4 °C), and the supernatants (10 µL) were injected onto an Atlantis HILIC column (150 × 2.1 mm, 3 µm particle size; Waters Inc.). The column was eluted isocratically at a flow rate of 250 µL/min with 5% mobile phase A (10 mM ammonium formate and 0.1% formic acid in water) for 1 min followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 min. The ion spray voltage was 4.5 kV and the source temperature was 450 °C.
A second method using basic HILIC separation and negative ionization mode MS detection was established on an LC-MS system consisting of an ACQUITY UPLC (Waters Inc.) coupled to a 5500 QTRAP triple quadrupole mass spectrometer (AB SCIEX). Plasma samples (30 µL) were extracted using 120 µL of 80% methanol (VWR) containing the internal standards inosine-15 N 4 , thymine-d 4 , and glycocholate-d 4 (Cambridge Isotope Laboratories). The samples were centrifuged (10 min, 9,000g, 4 °C), and the supernatants were injected directly onto a Luna NH2 column (150 × 2.0 mm, 5 µm particle size; Phenomenex) that was eluted at a flow rate of 400 µL/min with initial conditions of 10% mobile phase A (20 mM ammonium acetate and 20 mM ammonium hydroxide (Sigma-Aldrich) in water (VWR)) and 90% mobile phase B (10 mM ammonium hydroxide in 75:25 v/v acetonitrile/methanol (VWR)) followed by a 10-min linear gradient to 100% mobile phase A. The ion spray voltage was −4.5 kV and the source temperature was 500 °C.
Raw data were processed using MultiQuant 1.2 software (AB SCIEX) for automated LC-MS peak integration. All chromatographic peaks were manually reviewed for quality of integration and compared against a known standard for each metabolite to confirm compound identities. Internal standard peak areas were monitored for quality control, to assess system performance over time, and to identify any outlier samples requiring re-analysis. A pooled plasma reference sample was also analyzed after sets of 20 study samples as an additional quality control measure of analytical performance and to serve as reference for scaling raw LC-MS peak areas across sample batches. Metabolites with a signal-to-noise ratio <10 were considered unquantifiable. Metabolite signals were analyzed in relation to pancreatic cancer risk as LC-MS peak areas, which are proportional to metabolite concentration and appropriate for metabolite clustering and correlative analyses.
Of the 133 metabolites measured (Supplementary Note, Fig. S1 ), 83 were included in the analyses of our nested pancreatic cancer case-control population (Supplementary Note, Table S3 ). In pilot work 49 , we determined that 32 metabolites had poor reproducibility in samples with delayed processing, so these metabolites were excluded as they could not be reliably measured in two of the participating cohorts. In the current study, three heparin plasma pools (57 total QC samples) and three EDTA plasma pools (128 total QC samples) were randomly interspersed among participant samples as blinded QC samples. We calculated mean CVs for each metabolite across QC plasma pools and set an a priori threshold of ≤25% for satisfactory reproducibility. Based on this criterion, 13 metabolites with mean CV>25% were excluded from our analyses. Five metabolites had undetectable levels for >10% of participants and were also excluded. We evaluated plasma from ten volunteers with plasma collected simultaneously in heparin and EDTA tubes. For the branched chain amino acids, Spearman correlation coefficients between Heparin and EDTA samples were 0.85 for isoleucine, 0.88 for leucine, and 0.95 for valine.
For metabolites meeting the threshold for statistical significance after multiple-hypothesis correction (isoleucine, leucine and valine), LC-MS peak areas were converted to absolute concentrations using stable isotope-labeled standards. Briefly, external calibration curves of MS response were determined using solutions of isotope-labeled 13 C 6 , 15 N-leucine, 13 C 6 , 15 N-isoleucine (Cambridge Isotope Laboratories), and d 8 -valine (Isotec). A 1 µg/µL solution of each standard was prepared in water. 20 µL of each stock solution were added to 180 µL of reference pooled plasma, and the resulting solution was then serially diluted using pooled plasma to generate a calibration curve. For multiple reaction monitoring MS analyses, the bond cleavage products and collision energy (CE) and declustering potential (DP) settings were the same as those used for the endogenous metabolites: natural leucine 132/86, CE = 18 and DP = 50; 13 C 6 , 15 N-leucine 134/87, CE = 18 and DP = 50; natural isoleucine 132/86, CE = 18 and DP = 50; 13 C 6 , 15 N-isoleucine 139/92, CE = 18 and DP = 50; natural valine 118/72, CE = 18 and DP = 25, and d 8 -valine 126/80, CE = 18 and DP = 25.
Three separate plasma samples were prepared at each concentration and were analyzed using the acidic HILIC LC-MS method described above. The median concentrations of endogenous isoleucine, leucine and valine in the reference pooled plasma were calculated, and the concentration of each metabolite in each study sample was determined from the response ratio relative to the nearest reference pooled plasma sample in the analysis queue.
Statistical analyses for human studies.
To compare baseline characteristics, we used conditional logistic regression conditioned on the matching factors and including the covariate of interest. Partial Spearman correlation coefficients were calculated for metabolites and covariates. Metabolites were log-transformed to improve normality and included as continuous variables in conditional logistic regression models conditioned on matching factors and adjusted for age at blood draw (years, continuous), fasting time (< 4 h, 4-8 h, 8-12 h, ≥12 h, missing) and race or ethnicity (white, black, other, missing). Using a conservative Bonferroni correction for multiple-hypothesis testing 50 , metabolites with P ≤ 0.0006 (0.05/83) were considered statistically significant.
To provide estimates of effect magnitude, significant metabolites were examined in conditional logistic regression models after categorization into quintiles based on log-transformed metabolite levels in controls. Separate quintiles were generated for fasting (≥8 h since last meal) and nonfasting (<8 h since last meal) participants, given the possible effect of fasting time on metabolite levels. Quintiles were generated from the population of selected controls, which may not exactly reflect the characteristics of the full cohort population. Odds ratios (ORs) and 95% confidence intervals (CIs) were also calculated per s.d. change in log-transformed metabolite levels. To control for possible confounding, we evaluated regression models adjusted for body-mass index (BMI), physical activity, history of diabetes mellitus, HbA1c, plasma insulin, plasma proinsulin, and plasma C-peptide. We also evaluated regression models after excluding subjects with diabetes by self-report or HbA1c ≥6.5% at blood collection (prevalent diabetes). We further evaluated models that excluded subjects who developed diabetes after blood collection but >2 years before cancer diagnosis (incident diabetes not thought to be recent onset from pancreatic cancer) 42, 47 .
Metabolite values were considered missing when an LC-MS peak was below the limit of detection. In the primary analysis, any case or control with missing data for a metabolite was excluded from the analysis of that metabolite. However, we also conducted sensitivity analyses, in which participants with missing values were assigned the lower limit of detection or half of the lower limit of detection, and our results were unchanged.
We assessed heterogeneity of metabolite associations with pancreatic cancer risk across cohorts using Cochran's Q-statistic 51 . We examined associations in predefined subgroups by sex, smoking status, BMI, and fasting status. Statistical interactions were assessed by entering into models the main effect terms and cross-product terms of metabolites and stratification variables, evaluating likelihood ratio tests. We also examined associations by time between blood collection and the case's cancer diagnosis. In these time-based analyses, one stratum included 40 pancreatic cancer cases with blood collected within 2 years of diagnosis and their matched controls. These cases and controls were not part of the primary analysis population, but were included in the stratified analyses by time to more fully delineate the association of metabolites with pancreatic development by time before diagnosis. Associations were also examined for circulating BCAAs with previously explored risk factors for pancreatic cancer in our cohorts (Supplementary Note, Table S4 ) and with cancer stage at diagnosis (Supplementary Note, Table S5 ).
Since association of a marker with disease does not indicate the suitability of the marker to serve as a screening test for the disease, we examined two approaches to quantify the value of metabolites in a multifactor risk discrimination tool for pancreatic cancer. Discrimination quantifies the ability of one or more disease markers to separate cases (individuals with the disease) from controls (individuals without the disease). We investigated the discrimination of risk models for predicting pancreatic cancer diagnosis in the 10 years after measurement of circulating BCAAs, i.e., the 10-year risk of pancreatic cancer.
In the first approach, we investigated receiver-operating-characteristic (ROC) curve analysis and calculated of the area under the ROC curve (AUC), also known as the concordance (C) statistic 16, 52 . The base model included age at blood collection (continuous), cohort (HPFS, NHS, PHS, WHI; which also accounts for sex), race/ethnicity (white, black, other/missing), smoking status (never, past, current, missing) and fasting time (<4 h, 4-8 h, 8-12 h, ≥12 h, missing). Three subsequent models mirrored the base model but additionally included (1) body-mass index, physical activity, and history of diabetes, (2) circulating BCAAs, or (3) body-mass index, physical activity, history of diabetes, and circulating BCAAs. Each point on the ROC curve shows the effect of a rule for turning a risk estimate into a prediction of the development of an event. The y axis of the ROC curve is the true positive rate or sensitivity (i.e., the proportion of individuals with pancreatic cancer who were correctly predicted to have the disease). The x axis shows the false positive rate, which is the complement of specificity (i.e., the proportion of individuals without pancreatic cancer who were incorrectly predicted to have pancreatic cancer). The area under the ROC curve, the AUC, measures how well the model discriminates between case subjects and control subjects. An ROC curve that corresponds to a random classification of case subjects and control subjects is a straight line with an AUC of 50%. An ROC curve that corresponds to perfect classification has an AUC of 100%. The improvement in AUC for a model containing a new marker is defined as the difference in AUCs calculated using a model with and without the new marker of interest 53 .
For context, the Breast Cancer Risk Assessment Tool, commonly referred to as the Gail model 54, 55 , estimates a woman's risk for breast cancer using clinically available information including current age, age at menarche, age of first live birth, number of first-degree relatives with breast cancer, number of previous breast biopsies, breast biopsies that show atypical hyperplasia, and race/ethnicity. The Gail model is used to counsel women on appropriate screening tests for breast cancer 56 , for determining whether tamoxifen will be useful as a chemopreventative agent 57 , and for determining sample size calculations in randomized clinical trials of prevention strategies 58 . Several studies have evaluated the discrimination of the Gail model using ROC curve analysis and calculated the AUC to be 0.58 to 0.63 (refs. 52,59-61) . Follow-up studies have described an AUC of 0.62 to 0.66 when breast density is added as an additional predictor in the original Gail model 59, 60, 62 .
Although ROC curves are commonly used, they have a number of limitations and may underestimate the ability of a new marker to contribute to risk prediction when added to previously defined predictors [63] [64] [65] [66] . Another approach to evaluating model discrimination is to evaluate the ability of a new marker to shift an individual's risk up or down between predefined risk categories. This is known as the prediction increment of a marker and has been codified in an approach known as net reclassification improvement (NRI) 17 . The NRI (sometimes referred to as the net reclassification index) constructs reclassification tables separately for participants with and without events and quantifies the correct movement between categories of risk, namely, to higher risk categories for participants with events and to lower risk categories for those without events. Furthermore, incorrect movement in categories of risk (downwards for events and upwards for non-events) reduces the net correct reclassification of individuals within the study population.
The NRI calculation is represented by the following formula:
Upward movement (up) is defined as a change into a higher risk category based on the new model and downward movement (down) as a change into a lower risk category based on the new model, where P indicates probability and D denotes the event indicator (1, event; 0, non-event).
Using the NRI, we evaluated the ability of the prediction model including circulating BCAAs to appropriately reclassify individuals into risk groups compared to the base model. The base model was calculated using conditional logistic regression conditioned on matching factors and adjusted for race/ethnicity, body-mass index, physical activity and history of diabetes. The subsequent model included the covariates in the base model with the addition of circulating metabolites. As in prior studies [67] [68] [69] , we defined the high-risk group as those individuals with risk for pancreatic cancer at least twofold greater than an individual with average risk.
For context, the Emerging Risk Factors Collaboration 70 has examined the integration of novel risk factors into risk prediction models for cardiovascular disease. In these studies, additional potential risk predictors were added to a model of known risk predictors for cardiovascular disease, including age, sex, smoking status, blood pressure, history of diabetes, and cholesterol. The net reclassification improvement was then calculated for three 10-year risk categories for cardiovascular disease. C-reactive protein (CRP) is a marker of systemic inflammation, and elevated CRP has been associated with an increased risk for cardiovascular events in numerous studies [71] [72] [73] . Circulating CRP is currently used to inform decisions in the clinic regarding screening and risk reduction strategies 74, 75 and to design clinical trials testing novel treatments to reduce cardiovascular events 76, 77 . In an analysis of nearly 250,000 individuals 78 , the addition of CRP to know cardiovascular disease risk factors was associated with a statistically significant improvement in the area under the ROC curve and a NRI of 1.52% for 10-year risk of cardiovascular disease. In contrast, additional analyses demonstrated a <1% improvement in the NRI for body-mass index, waist circumference, waist-to-hip ratio, plasma fibrinogen, and circulating apolipoproteins [78] [79] [80] , such that the clinical utility of these additional predictors remains unclear 75 .
All analyses were performed with SAS 9.2 statistical package. All P values were two-sided.
Experimental mice. All studies were approved by the MIT Committee on Animal Care (IACUC). All experimental groups were assigned based on genotype. All animals were numbered and experiments conducted blinded. After data collection, genotypes were revealed and animals assigned to groups for analysis. The experiments were not randomized.
KPC. Experimental KPC mice were male mice on a mixed background, heterozygous for the conditional lox-stop-lox Kras G12D allele, heterozygous for the conditional lox-stop-lox Trp53 R172H allele and expressing Cre recombinase under control of the Pdx1 promoter (Tg(Ipf1-cre)1 Tuv ) 19 . Littermate controls lacked either the LSL-Kras G12D allele, the Cre allele or both. Control mice were killed at the same time as their tumor-bearing littermates.
KP −/− C. Experimental KP −/− C mice were male mice on a mixed background, heterozygous for the conditional lox-stop-lox Kras G12D allele, homozygous for loxP sites flanking exons 2-10 of Trp53 and expressing Cre recombinase under control of the Pdx1 promoter (Tg(Ipf1-cre)1 Tuv ) 20 . Littermate control mice lacked either the Cre-recombinase allele, LSL-Kras G12D allele or both (controls were non-tumor-bearing mice of all genotypes). Inbred C57BL/6J male mice containing the same alleles were also examined where indicated, and cancer cell lines derived from these mice (established in culture from tumors prior to the described implantation studies) were used for syngenic implantation studies.
Non-small-cell lung cancer. Six-month-old male mice on a pure 129 background, heterozygous for the conditional lox-stop-lox Kras G12D allele and homozygous for loxP sites flanking exons 2-10 of Trp53, were administered 2.5 × 10 7 PFU of Cre-expressing adenovirus intratracheally as previously described 21, 22 . High-titer adenovirus was obtained from the Gene Transfer Vector Core (University of Iowa).
Hindlimb sarcoma. Four-week-old male mice on a mixed background, heterozygous for the conditional lox-stop-lox Kras G12D allele and homozygous for loxP sites flanking exons 2-10 of Trp53 were administered 2.5×10 8 PFU of Cre-expressing adenovirus intramuscularly as previously described 23 . High-titer adenovirus was obtained from the Gene Transfer Vector Core (University of Iowa).
Implantation, pancreatitis and BCAA diet studies. Male C57BL/6J mice aged 4-6 weeks at the start of the study were used for these experiments.
Diets. Standard chow diet was RMH 3000 (Prolab). For amino acid-defined diets, 1× BCAA (TD.110839) and 2× BCAA (TD.110843) were designed in consultation with and subsequently obtained from Harlan Teklad. 20% 13 C-leucine-and 20% 13 C-valine-labeled diets were based on diet TD.110839 and produced by Cambridge Isotopes and Harlan Teklad.
Plasma for metabolomics. Plasma was collected for each experiment at the time points indicated. Mice were anesthetized under 2% isoflurane-oxygen mixture and retro-orbitally bled approximately 4.5 h after the onset of the light cycle. Blood was immediately placed in EDTA-pretreated tubes and centrifuged to separate plasma. Plasma was aliquoted and frozen at −80 °C for further analysis. npg repeated-measures analysis of variance was performed to compare mean plasma glucose levels in the glucose tolerance test and insulin tolerance tests 85 , using SAS 9.2 statistical package. No statistical method was used to predetermine sample size.
